Welcome to our dedicated page for DAXOR SEC filings (Ticker: DXR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Daxor Corporation filings document material events, capital-structure activity, governance votes, and regulatory disclosures for a Nasdaq-listed medical instrumentation and biotechnology company focused on blood volume measurement. Recent 8-K filings describe registered common-stock offerings, securities purchase and placement agency agreements, investor presentation materials, and the company’s common stock registration on Nasdaq.
The filing record also includes disclosures tied to FDA clearance for Daxor’s rapid, portable lab-based Blood Volume Analysis system, as well as annual meeting results covering director elections and auditor ratification. These documents frame the company’s formal reporting around BVA commercialization, financing, shareholder governance, and public-company compliance.
Daxor Corporation filed a current report to share its latest investor presentation with the market. The company used an 8-K under the "Other Events" section to formally furnish this material.
The filing states that the current investor presentation is attached as Exhibit 99.1, making it part of the public record. Daxor’s common stock, with a par value of $0.01 per share, trades on Nasdaq under the symbol DXR.
Daxor Corporation has filed a base prospectus to offer up to $25,000,000 of its common stock from time to time and to register shares for resale by the Joseph Feldschuh Estate. The company may sell shares directly, through agents or underwriters, with specific terms and pricing to be detailed in future prospectus supplements. Net proceeds from primary sales are expected to support working capital, product development, capital expenditures, potential investments or acquisitions, and debt repayment, with unused funds invested in investment-grade preferred securities.
The prospectus also registers common stock held by the Joseph Feldschuh Estate, which controls more than 50% of Daxor’s voting power; all proceeds from those resales will go to the selling shareholder, not the company. Daxor operates its BVA-100 blood volume analyzer and Volumex diagnostic kit from its Oak Ridge, Tennessee facility and relies heavily on an investment portfolio concentrated in electric utility stocks. The company intends to seek deregistration as a closed-end investment company, which would remove Investment Company Act protections for investors and could change its tax treatment; if that order is granted, offerings under this document would cease and be shifted to a different registration format.
Daxor Corp reported an insider equity transaction by its Chief Financial Officer, Robert J. Michel. On December 9, 2025, he acquired 3,000 shares of Daxor common stock at a stated price of $0, reflecting the vesting of a stock grant.
Following this transaction, the CFO beneficially owns 20,050 shares of Daxor common stock in direct ownership, according to the Form 4 disclosure.
Daxor Corp (DXR) reported an insider equity event by its Chief Medical Officer, John Jefferies. On November 12, 2025, he acquired 2,344 shares of Daxor common stock at a reported price of $0, coded as “P,” with the filing noting these shares were from a grant that vested on November 12, 2025.
Following this transaction, Jefferies beneficially owns 17,616 shares with direct ownership. The filing was made by one reporting person and identifies his role as Officer (Chief Medical Officer).
John Jefferies, Chief Medical Officer of DAXOR CORP (DXR), filed an Initial Statement of Beneficial Ownership reporting 15,272 shares of DAXOR common stock owned directly. The filing lists multiple stock options exercisable for a total of ≈18,181 underlying shares across various grant dates and strike prices, with several tranches vesting by 12/01/2025 and one option presently exercisable in full.
Daxor (DXR) filed a routine Form 4 disclosing that director Henry D. Cremisi received an option grant for 2,500 common-stock shares on June 24 2025 under the company’s 2020 Incentive Compensation Plan, contingent upon SEC approval of an amendment to that plan. The options carry a $9.29 exercise price and vest in three annual tranches (833/883/834 shares through 2027). No DXR shares were bought or sold, and Cremisi’s beneficial ownership now includes the new grant. The filing does not report any other transactions or material changes.
Daxor – DXR filed a Form 4 reporting that director Edward Feuer was granted 2,500 stock options on 24 June 2025 at an exercise price of $9.29. The award is contingent on SEC approval of an amendment to the company’s 2020 Incentive Compensation Plan.
The options vest in three tranches—833 on 24 Jun 2025, 883 on 24 Jun 2026 and 834 on 24 Jun 2027—and expire on 24 Jun 2030. No common shares were bought or sold, and beneficial ownership remains solely derivative. The filing represents routine equity compensation rather than an open-market transaction.